NAFLD and NASH Treatments

Non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH), are increasingly recognized as major contributors to liver disease and metabolic syndrome. Advances in NAFLD and NASH treatments are bringing promising new options for managing these conditions. Recent developments include novel pharmacological agents aimed at reducing liver inflammation and fibrosis. Medications like obeticholic acid and elafibranor are being investigated for their potential to improve liver histology and metabolic parameters. Lifestyle modifications remain crucial, with weight loss through diet and exercise proving effective in reducing liver fat and inflammation. Emerging therapies also include anti-fibrotic agents and medications targeting specific pathways involved in lipid metabolism and inflammation. Additionally, advancements in non-invasive diagnostic tools, such as imaging techniques and biomarkers, are enhancing early detection and monitoring of disease progression. These innovations are improving treatment options, offering hope for better management and potentially reversing the course of NAFLD and NASH.

    Related Conference of NAFLD and NASH Treatments

    May 21-22, 2026

    17th International Conference on Liver Diseases & Hepatology

    Aix-en-Provence, France
    June 18-19, 2026

    9th International Congress on Viral Hepatitis

    Paris, France
    June 29-30, 2026

    5th International Conference on Gastroenterology and Liver

    Aix-en-Provence, France
    August 03-04, 2026

    21st Euro-Global Gastroenterology Conference

    London, UK
    September 29-30, 2026

    7th Global Summit on Earth Science and Climate Change

    Aix-en-Provence, France

    NAFLD and NASH Treatments Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in